RD Fund

The Retinal Degeneration Fund (RD Fund) functions as a strategic investment vehicle dedicated to accelerating the development of novel therapies for inherited retinal diseases. As the venture arm of the Foundation Fighting Blindness, it deploys capital into promising biotechnology companies and research initiatives, aiming to bridge the gap between scientific discovery and clinical application. The fund focuses on building a robust pipeline of treatments that address a spectrum of retinal degenerations.

The RD Fund was formally launched in 2018, originating from the long-standing efforts of the Foundation Fighting Blindness, established in 1971. This strategic pivot was driven by the insight that a dedicated venture arm could more effectively catalyze the translation of foundational research into tangible therapeutic solutions. The Foundation’s deep expertise and network in retinal science provided a unique platform for this investment strategy.

The primary beneficiaries of the RD Fund's activities are individuals worldwide affected by inherited retinal degenerative diseases. By strategically investing, the organization seeks to deliver life-changing treatments to patients in need today, while also cultivating future generations of therapies. Its vision is centered on ultimately eradicating blindness caused by these debilitating conditions through focused investment and scientific advancement.